<DOC>
	<DOCNO>NCT00454571</DOCNO>
	<brief_summary>This randomized phase II trial study well pazopanib hydrochloride work leuprolide goserelin treat patient relapsed prostate cancer . Pazopanib hydrochloride may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Androgens cause growth prostate cancer cell . Antihormone therapy , leuprolide acetate goserelin acetate , may lessen amount androgen make body . Giving pazopanib leuprolide goserelin may effective treatment prostate cancer</brief_summary>
	<brief_title>Pazopanib Hydrochloride After Leuprolide Acetate Goserelin Acetate Treating Patients With Relapsed Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine pazopanib hydrochloride able increase time progression , measure prostate-specific antigen ( PSA ) , 6 month limit gonadotropin-releasing hormone ( GnRH ) agonist therapy comprise leuprolide acetate goserelin patient androgen-sensitive relapsed stage D0 prostate cancer . SECONDARY OBJECTIVES : I . Determine adverse event patient treat regimen . II . To monitor change testosterone relationship pazopanib therapy versus observation . OUTLINE : Patients receive androgen blockade comprise GnRH agonist therapy ( e.g. , leuprolide acetate goserelin acetate ) 6 month . Patients develop metastasis PSA progression GnRH agonist therapy remove study place total androgen blockade . The remain patient randomize 1 2 treatment arm . ARM I : Patients receive pazopanib hydrochloride orally ( PO ) daily ( QD ) day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . ARM II : Patients undergo observation . After completion study treatment , patient follow periodically 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Histologically cytologically confirm prostate cancer Stage D0 Must undergone definitive local therapy prostate cancer Must free macrometastatic disease , evidence compute tomography ( CT ) scan bone scan , serum PSA ≥ 10 ng/mL prior GnRH agonist therapy Progressive disease meeting follow criterion : NOTE : Patients undergone prostatectomy two detectable , rise serum PSA level eligible Two consecutive rise PSA nadir record definite local therapy Serum PSA concentration must absolute value &gt; 0.5 ng/mL ( separate ≥ 2 week ) prior begin GnRH agonist therapy PSA &lt; 0.5 ng/mL Testosterone &lt; 30 ng/mL No measurable disease No brain metastasis require steroid anticonvulsant therapy Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 OR Karnofsky PS 60 100 % Prothrombin time ( PT ) /international normalization ratio ( INR ) /partial thromboplastin time ( PTT ) ≤ 1.2 time upper limit normal ( ULN ) Bilirubin normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance &gt; 50 mL/min Proteinuria ≤ 1+ 2 consecutive dipstick &gt; 1 week apart Urine protein : creatinine ratio &lt; 1 OR urine protein &lt; 1.0 g/24 hour Fertile patient must use effective doublebarrier contraception study therapy OR completely abstain sexual intercourse 14 day prior , , ≥ 21 day completion study therapy No history allergic reaction attribute compound similar chemical biological composition pazopanib hydrochloride agent use study No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Psychiatric illness social situation would preclude compliance study requirement No human immunodeficiency virus ( HIV ) positivity No condition impair ability swallow retain pazopanib hydrochloride tablet , include follow : Gastrointestinal tract disease result inability take oral medication Requirement intravenous ( IV ) alimentation Prior surgical procedure affect absorption Active peptic ulcer disease No condition , include follow : Serious nonhealing wound , ulcer , bone fracture Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day Cerebrovascular accident within past 6 month Myocardial infarction , admission unstable angina , cardiac angioplasty , stenting within past 6 month Venous thrombosis within past 12 week New York Heart Association ( NYHA ) class III IV heart failure History currently treat asymptomatic NYHA class II heart failure allow Systolic blood pressure ( BP ) ≤ 140 mm Hg diastolic BP ≤ 90 mm Hg Prior initiation adjustment BP medication allow provided average 3 BP reading visit prior enrollment &lt; 140/90 mm Hg More 3 month since prior antiandrogen More 4 month since prior orchiectomy implantable luteinizing LHRH agonist No prior GnRH agonist except neoadjuvant adjuvant therapy associate local therapy Patients start GnRH agonist micrometastatic disease local therapy allow provide follow criterion meet : Progressive disease Willing discontinue therapy 6 month elapse Have sign consent prior complete 6 month initial hormone therapy Are within 4 month initiate GnRH agonist therapy No prior concurrent GnRH antagonist therapy No concurrent ketoconazole No concurrent cytochrome P450 2C9 ( CYP2C9 ) substrates , include follow : Anticoagulants ( e.g. , warfarin [ therapeutic dos ] ) Low molecular weight heparin prophylactic lowdose warfarin allow Oral hypoglycemics ( e.g. , glipizide , glyburide , tolbutamide , glimepiride , nateglinide ) Ergot derivative ( e.g. , dihydroergotamine , ergonovine , ergotamine , methylergonovine ) Neuroleptics ( e.g. , pimozide ) Erectile dysfunction agent ( e.g. , sildenafil , tadalafil , vardenafil ) Antiarrhythmics ( e.g. , bepridil , flecainide , lidocaine , mexiletin , amiodarone , quinidine , propafenone ) Immune modulators ( e.g. , cyclosporine , tacrolimus , sirolimus ) Miscellaneous medication ( e.g. , theophylline , quetiapine , risperidone , tacrine , clozapine , atomoxetine ) No concurrent medication associate risk QTc prolongation and/or Torsades de Pointes Replacement drug carry risk allow No concurrent nonFood Drug Administration ( FDA ) approve agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>